Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Warning issued over eye exposure to ear drops
EMA said veterinary surgeons should advise pet owners to take care when applying Osurnia.
Reports of eye injuries in people and pets after accidental exposure 

The European Medicines Agency has issued a warning about accidental exposure to Osurnia ear gel for dogs, after a number of pets and owners suffered eye injuries.

Injuries reported in people include two cases of corneal ulcers, as well as complaints of eye irritation, conjunctivitis, redness, during, stinging and itchiness. In dogs, there were reports of corneal ulcers, squinting, impaired vision, conjunctivitis, redness and swelling around the eye.

Eye exposure in humans largely occurred when the dog shook its head during or just after the medication was applied to the ear.

Veterinary professionals will be informed about this issue in writing and are being encouraged to report any suspected side effects to the relevant national authority, or the manufacturer of Osurnia, Elanco Europe Ltd.

EMA said veterinary surgeons should advise pet owners to take care when applying Osurnia, taking appropriate measures to ensure the product does not contact the eyes of people or dogs. This includes restraining the animal’s head while the medicine is applied.

If accidental exposure does occur, rinse the eyes thoroughly with water for 10-15 minutes and seek medical care.

Pet owners should also monitor dogs treated with the product and contact their vet if they notice any side effects, particularly those affecting the eyes.

EMA says it will continue to monitor the safety of the medicine and will take regulatory action as appropriate.

Become a member or log in to add this story to your CPD history

Greyhound Board announces change to vaccination guidance

News Story 1
 The Greyhound Board of Great Britain has published new vaccination guidance, with all greyhounds registered from 1 January, 2027 required to have the L4 leptospirosis vaccination, rather than L2.

The change comes in response to the reduced availability of the 'L2' Leptospirosis vaccine across the UK, and aims to support best biosecurity practice across the racing greyhound population.

GBGB veterinary director Simon Gower, said "While rare, Leptospirosis is a serious infectious disease that can affect both dogs and humans, so it is vital that we offer our greyhounds the broadest possible protection.  

Click here for more...
News Shorts
Free webinar explores congenital heart disease in dogs

A free webinar is to provide veterinary professionals, dog breeders and pet owners an new insights into congenital heart disease.

Chris Linney, a cardiology specialist and Veterinary Cardiovascular Society (VSC) member, will present the webinar from 7.00pm to 8.30pm on Wednesday, 12 November.

Dr Linney will explore the types, causes and clinical presentation of congenital heart conditions. This will include diagnostic approaches, treatment pathways and emerging research opportunities.

The session is the third to be organised by The Kennel Club, with the VCS, following an introductory webinar and a talk on acquired heart disease. Dr Linney's webinar consists of a one-hour presentation, followed by a 30-minute question and answer session.

Dr Linney said: "This webinar will be an opportunity to deepen understanding - not just of the diseases themselves, but of how breeders, vets and owners can work together to support affected dogs and improve outcomes for future generations."

Click here to register for the webinar.